Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook — Oct 10th, 2024

Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review — Oct 7th, 2024

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which a...

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details — Oct 10th, 2024

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...

Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... — Oct 11th, 2024

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics. SUBLOCADE Long-Term Potential: Greater than $1.5 billion peak net revenue potential. Market ...

Indivior price target lowered to $16 from $20 at Craig-Hallum — Oct 12th, 2024

Craig-Hallum lowered the firm’s price target on Indivior to $16 from $20 and keeps a Buy rating on the shares. While Q3 pre-released results were relatively in-line and ahead of expectations on the overall top-line, FY24 guidance was revised lower in what the firm calls “a disappointin...

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion — Oct 10th, 2024

Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10,...